503b glp 1 Compounded Semaglutide & Tirzepatide 2025: Safe Use Guide Fifth Circuit probes FDA ban

This is the breakdown by drug, plan type, and indication for 2026

doi:10.1007/s10620-023-08122-w

Additionally, its important to discuss any other medications you may be taking with the prescribing healthcare professional

What changed on April 30, 2026: The FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list

For those who may be worried about affording the name-brand GLP-1 medications, Ewing said it is always worthwhile to check with your insurance provider about their coverage for weight-loss medications, as formularies can change, and what was not covered before might be now